The prognostic role of tissue TLR2 and TLR4 in colorectal cancer.
Aged
Biomarkers, Tumor
/ analysis
Colorectal Neoplasms
/ chemistry
Female
Finland
Humans
Immunohistochemistry
Male
Middle Aged
Neoplasm Grading
Neoplasm Staging
Predictive Value of Tests
Retrospective Studies
Risk Assessment
Risk Factors
Tissue Array Analysis
Toll-Like Receptor 2
/ analysis
Toll-Like Receptor 4
/ analysis
Colon cancer
Colorectal cancer
Immunohistochemistry
Toll-like receptor 2
Toll-like receptor 4
Journal
Virchows Archiv : an international journal of pathology
ISSN: 1432-2307
Titre abrégé: Virchows Arch
Pays: Germany
ID NLM: 9423843
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
02
10
2019
accepted:
28
04
2020
revised:
17
04
2020
pubmed:
20
5
2020
medline:
3
11
2020
entrez:
20
5
2020
Statut:
ppublish
Résumé
Colorectal cancer (CRC), the second most common cancer globally, resulted in 881,000 deaths in 2018. Toll-like receptors (TLRs) are crucial to detecting pathogen invasion and inducing the host's immune response. This study aimed to explore the prognostic value of TLR2 and TLR4 tumor expressions in colorectal cancer patients. We studied the immunohistochemical expressions of TLR2 and TLR4 using tissue microarray specimens from 825 patients undergoing surgery in the Department of Surgery, Helsinki University Hospital, between 1982 and 2002. We assessed the relationships between TLR2 and TLR4 expressions and clinicopathological variables and patient survival. We generated survival curves using the Kaplan-Meier method, determining significance with the log-rank test. Among patients with lymph node-positive disease and no distant metastases (Dukes C), a strong TLR2 immunoactivity associated with a better prognosis (p < 0.001). Among patients with local Dukes B disease, a strong TLR4 immunoactivity associated with a worse disease-specific survival (DSS; p = 0.017). In the multivariate survival analysis, moderate TLR4 immunoactivity compared with strong TLR4 immunoactivity (hazard ratio (HR) 0.66, 95% confidence interval (CI) 0.49-0.89, p = 0.007) served as an independent prognostic factor. In the multivariate analysis for the Dukes subgroups, moderate TLR2 immunoactivity (HR 2.63, 95% CI 1.56-4.44, p < 0.001) compared with strong TLR2 immunoactivity served as an independent negative prognostic factor in the Dukes C subgroup. TLR2 and TLR4 might be new prognostic factors to indicate which CRC patients require adjuvant therapy and which could spare from an unnecessary follow-up, but further investigations are needed.
Identifiants
pubmed: 32424768
doi: 10.1007/s00428-020-02833-5
pii: 10.1007/s00428-020-02833-5
pmc: PMC7581516
doi:
Substances chimiques
Biomarkers, Tumor
0
TLR2 protein, human
0
TLR4 protein, human
0
Toll-Like Receptor 2
0
Toll-Like Receptor 4
0
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
705-715Références
Oncogene. 2008 Jan 7;27(2):225-33
pubmed: 18176604
Tumour Biol. 2018 Sep;40(9):1010428318801188
pubmed: 30246618
Cancer Immunol Immunother. 2010 Jul;59(7):1021-8
pubmed: 20177675
Cancer Immunol Immunother. 2011 Feb;60(2):217-26
pubmed: 20978888
BMC Cancer. 2010 Dec 03;10:665
pubmed: 21129170
Mol Biol Rep. 2009 Jul;36(6):1475-81
pubmed: 18763053
Eur J Surg Oncol. 2007 Sep;33(7):849-53
pubmed: 17379473
Acta Oncol. 2008;47(4):591-9
pubmed: 18465327
J Immunother. 2010 Jan;33(1):73-82
pubmed: 19952954
Oral Oncol. 2015 Jan;51(1):96-102
pubmed: 25264223
J Clin Pathol. 2012 Apr;65(4):333-8
pubmed: 22267982
Updates Surg. 2016 Mar;68(1):7-11
pubmed: 27067591
Br J Surg. 2012 May;99(5):714-20
pubmed: 22311576
Diabetes Care. 2010 Apr;33(4):861-8
pubmed: 20067962
Int J Mol Med. 2007 Jul;20(1):21-9
pubmed: 17549384
BMC Cancer. 2014 May 16;14:336
pubmed: 24886281
Nat Rev Immunol. 2013 Jun;13(6):453-60
pubmed: 23681101
J Clin Endocrinol Metab. 2008 Feb;93(2):578-83
pubmed: 18029454
Arch Dermatol Res. 2013 Jan;305(1):59-67
pubmed: 23179584
Nat Immunol. 2004 Oct;5(10):987-95
pubmed: 15454922
Gut. 2017 Apr;66(4):683-691
pubmed: 26818619
Cancer Immunol Immunother. 2012 Jan;61(1):71-7
pubmed: 21845432
Int J Colorectal Dis. 2016 Sep;31(9):1577-94
pubmed: 27469525
Acta Oncol. 2013 Nov;52(8):1691-8
pubmed: 24102179
Int Immunopharmacol. 2018 Jun;59:391-412
pubmed: 29730580
World J Gastroenterol. 2017 Jul 14;23(26):4831-4838
pubmed: 28765705
World J Gastrointest Oncol. 2015 Aug 15;7(8):111-7
pubmed: 26306143
World J Surg Oncol. 2012 Sep 17;10:193
pubmed: 22985132
Cancer Microenviron. 2009 Sep;2 Suppl 1:205-14
pubmed: 19685283
Oncotarget. 2016 Apr 26;7(17):23658-67
pubmed: 27008696
J Cell Mol Med. 2010 Nov;14(11):2592-603
pubmed: 20629986
Acta Oncol. 2015 Jan;54(1):5-16
pubmed: 25430983
Immunobiology. 2017 Jan;222(1):89-100
pubmed: 27349597
Eur J Cancer. 2014 Jan;50(2):309-19
pubmed: 24103145
Arch Pharm Res. 2012 Aug;35(8):1297-316
pubmed: 22941474
J Immunother. 2013 Jul-Aug;36(6):342-9
pubmed: 23799413
Gastroenterology. 2003 Jan;124(1):140-6
pubmed: 12512038
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Gastroenterology. 2007 Dec;133(6):1869-81
pubmed: 18054559
Oncogene. 2008 Jan 7;27(2):218-24
pubmed: 18176603
J Oral Pathol Med. 2016 May;45(5):338-45
pubmed: 26426362
Cancer Cell. 2012 Oct 16;22(4):466-78
pubmed: 23079657
J Immunol Res. 2015;2015:489821
pubmed: 26090491
Int Immunopharmacol. 2007 Oct;7(10):1271-85
pubmed: 17673142